Presentations by Program

In vitro activity of sulbactam-durlobactam against Acinetobacter baumannii-calcoaceticus complex isolates from a five-year surveillance program (2016 – 2020)

Meredith Hackel, Sarah McLeod, Alita Miller and Daniel Sahm (ECCMID, 2022)

Safety profile of sulbactam-durlobactam (SUL-DUR) versus colistin therapy in patients with Acinetobacter baumannii-calcoaceticus complex (ABC) infections from the global, randomized, active-controlled phase 3 trial (ATTACK)

Drew Lewis, Khurram Rana, Melissa Steidler, Gabrielle Poirier and David Altarac (ECCMID, 2022)

Sulbactam-durlobactam (SUL-DUR) in vitro dose response studies with and without imipenem or meropenem against carbapenemase-producing Acinetobacter baumannii utilizing the hollow-fiber infection model

John O'Donnell, Angela Tanudra, Sarah McLeod, Alita Miller and Ruben Tommasi (ECCMID, 2022)

Characterization of co-infecting Gram-negative pathogens isolated in addition to Acinetobacter baumannii-calcoaceticus complex (ABC) at baseline from patients enrolled in the ATTACK phase 3 trial

Alita Miller, Sarah McLeod, Daria Chabas, Gabrielle Poirier, and David Altarac (ECCMID, 2022)

Efficacy and safety of sulbactam-durlobactam (SUL-DUR) therapy in patients with Acinetobacter baumannii-calcoaceticus complex (ABC) infections in the open label Part B of the ATTACK phase 3 trial

Khurram Rana, David Altarac, Robin Isaacs, Subasree Srinivasan, Sarah McLeod, Gabrielle Poirier, Andrew Shorr and Keith Kaye (ECCMID, 2022)

Characterization of Acinetobacter baumannii-calcoaceticus complex (ABC) pathogens isolated at baseline from patients enrolled in the ATTACK phase 3 trial

Alita Miller, Sarah McLeod, Daria Chabas, Gabrielle Poirier and David Altarac (ECCMID, 2022)

Efficacy and safety of sulbactam-durlobactam (SUL-DUR) versus colistin therapy in patients with Acinetobacter baumannii-calcoaceticus complex (ABC) infections: a global, randomized, active-controlled phase 3 trial (ATTACK)

David Altarac, Robin Isaacs, Subasree Srinivasan, Sarah McLeod, Khurram Rana, Gabrielle Poirier, Andrew Shorr and Keith Kaye (ECCMID, 2022)

Discovery of ETX0462, a novel non-β-lactam PBP inhibitor to treat Gram-negative infections, including MDR Pseudomonas aeruginosa

Thomas Durand-Reville (SCI-RSC, 2021)

In Vitro Activity of Sulbactam-Durlobactam against Recent Clinical Acinetobacter baumannii-calcoaceticus Complex Isolates

Sarah McLeod, Samir Moussa, Meredith Hackel and Alita Miller (ECCMID, 2021)

The β-lactamase inhibitor ETX1317 restores the activity of cefpodoxime against recent (2017 2019), geographically diverse drug resistant Enterobacterales isolates

Sarah McLeod, Michael Huband, Jennifer Thompson, John Mueller and Alita Miller (Microbe, 2021)